EVOKE PHARMA INC (EVOK) Stock Price, Forecast & Analysis
NASDAQ:EVOK • US30049G3020
EVOK Key Statistics, Chart & Performance
The current stock price of EVOK is 11 USD. In the past month the price increased by 2.9%. In the past year, price increased by 116.96%.
EVOK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EVOK. When comparing the yearly performance of all stocks, EVOK is one of the better performing stocks in the market, outperforming 97.83% of all stocks.
EVOK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EVOK. Both the profitability and financial health of EVOK have multiple concerns.
EVOK Financial Highlights
Over the last trailing twelve months EVOK reported a non-GAAP Earnings per Share(EPS) of -2.21. The EPS increased by 79.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.4% | ||
| ROE | -155.44% | ||
| Debt/Equity | 1.49 |
EVOK Forecast & Estimates
6 analysts have analysed EVOK and the average price target is 18.36 USD. This implies a price increase of 66.91% is expected in the next year compared to the current price of 11.
For the next year, analysts expect an EPS growth of 57.76% and a revenue growth 59.35% for EVOK
EVOK Ownership
EVOK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.05 | 985.228B | ||
| JNJ | JOHNSON & JOHNSON | 21.14 | 593.362B | ||
| MRK | MERCK & CO. INC. | 22.9 | 307.597B | ||
| PFE | PFIZER INC | 9.04 | 154.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.12 | 125.402B | ||
| ZTS | ZOETIS INC | 18.73 | 56.699B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.207B | ||
| VTRS | VIATRIS INC | 6.35 | 18.503B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.23 | 13.107B | ||
| AXSM | AXSOME THERAPEUTICS INC | 207.52 | 8.567B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EVOK
Company Profile
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Company Info
EVOKE PHARMA INC
420 Stevens Avenue, Suite 230
Solana Beach CALIFORNIA 92075 US
CEO: David A. Gonyer
Employees: 3
Phone: 18583451494
EVOKE PHARMA INC / EVOK FAQ
Can you describe the business of EVOKE PHARMA INC?
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Can you provide the latest stock price for EVOKE PHARMA INC?
The current stock price of EVOK is 11 USD. The price increased by 0.36% in the last trading session.
What is the dividend status of EVOKE PHARMA INC?
EVOK does not pay a dividend.
How is the ChartMill rating for EVOKE PHARMA INC?
EVOK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does EVOKE PHARMA INC have?
EVOKE PHARMA INC (EVOK) currently has 3 employees.
Can you provide the market cap for EVOKE PHARMA INC?
EVOKE PHARMA INC (EVOK) has a market capitalization of 18.92M USD. This makes EVOK a Nano Cap stock.
Can you provide the ownership details for EVOK stock?
You can find the ownership structure of EVOKE PHARMA INC (EVOK) on the Ownership tab.